Abstract
The old-fashioned anticancer approaches, aiming at arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual singletarget drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of a multi-target approach, the closely related evolutionary members of the tyrosine kinase family are ideal candidates. Indeed, tyrosine kinase activities are not only critical in tumor phenotype maintenance, but also modulate several functions in the tumor microenvironment. Consequently, several multikinase inhibitors were approved in the last decade, and many new molecules are currently in preclinical or clinical development. In the present review we report on the most widely FDA-approved multitargeted drugs, discussing about their mechanism of action and outlining the clinical trials that have brought them to approval.
Keywords: Multitargeted drugs, anticancer agents, polypharmacology, tyrosine kinase receptors, oncogene addiction, tumor microenvironment, FDA-approved drugs.
Current Medicinal Chemistry
Title:Kinase Inhibitors in Multitargeted Cancer Therapy
Volume: 24 Issue: 16
Author(s): Carla Gentile, Annamaria Martorana, Antonino Lauria*Riccardo Bonsignore
Affiliation:
- Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche “STEBICEF” - Università di Palermo, Viale delle Scienze - Ed. 17 -90128 Palermo,Italy
Keywords: Multitargeted drugs, anticancer agents, polypharmacology, tyrosine kinase receptors, oncogene addiction, tumor microenvironment, FDA-approved drugs.
Abstract: The old-fashioned anticancer approaches, aiming at arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual singletarget drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of a multi-target approach, the closely related evolutionary members of the tyrosine kinase family are ideal candidates. Indeed, tyrosine kinase activities are not only critical in tumor phenotype maintenance, but also modulate several functions in the tumor microenvironment. Consequently, several multikinase inhibitors were approved in the last decade, and many new molecules are currently in preclinical or clinical development. In the present review we report on the most widely FDA-approved multitargeted drugs, discussing about their mechanism of action and outlining the clinical trials that have brought them to approval.
Export Options
About this article
Cite this article as:
Gentile Carla, Martorana Annamaria, Lauria Antonino*, Bonsignore Riccardo, Kinase Inhibitors in Multitargeted Cancer Therapy, Current Medicinal Chemistry 2017; 24 (16) . https://dx.doi.org/10.2174/0929867324666170112112734
DOI https://dx.doi.org/10.2174/0929867324666170112112734 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry In Vitro Methods to Study the Interplay of Drug Metabolism and Efflux in the Intestine
Current Drug Metabolism Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Evaluation of High Risk HPV (HPV-16 and -18) RNA and Integration in Cervical Neoplasms in Systemic Lupus Erythematosus
Current Women`s Health Reviews Copper Complexes as Antitumor Agents: <i>In vitro</i> and <i>In vivo</i> Evidence
Current Medicinal Chemistry Body Fluids-Derived Exosomes: Paving the Novel Road to Lung Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Advanced Vectors for Gene Delivery
Current Drug Therapy Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets